DNM1L and breast cancer: Inhibition of DRP1 through siRNA or pharmacological inhibition with Mdivi-1—an established inhibitor of DRP1—reduced migratory and invasive phenotypes found in these highly metastatic breast cancer cell lines (Zhao et al., 2013).